Medicine and Dentistry
Patient
100%
Immunoglobulin
66%
Low Drug Dose
38%
Chronic Inflammatory Demyelinating Polyneuropathy
38%
Drug Megadose
33%
Maintenance Therapy
16%
Therapeutic Procedure
16%
Adverse Event
11%
Intention-to-Treat Analysis
11%
Personnel
11%
Caregiver
11%
Adult
11%
Amaurosis
11%
Recurrence Risk
5%
Risk Reduction
5%
Skin Allergy
5%
Polyneuropathy
5%
Obstetric Delivery
5%
Voice
5%
Human Albumin
5%
Relapse
5%
INIS
doses
83%
immunoglobulins
66%
patients
55%
inflammation
38%
maintenance
16%
japan
16%
solutions
11%
humans
5%
risks
5%
personnel
5%
adults
5%
comparative evaluations
5%
size
5%
delivery
5%
skin
5%
administration
5%
israel
5%
reduction
5%
europe
5%
assignments
5%
north america
5%
australia
5%
albumins
5%
Nursing and Health Professions
Immunoglobulin
66%
Placebo
55%
Low Drug Dose
38%
Chronic Inflammatory Demyelinating Polyneuropathy
38%
Drug Megadose
33%
Maintenance Therapy
16%
Adverse Event
11%
Intention to Treat Analysis
11%
Dose
11%
Inpatient
11%
Blindness
11%
Randomization
5%
Recurrence Risk
5%
Skin Allergy
5%
Polyneuropathy
5%
Obstetric Delivery
5%
Procedures
5%
Relapse
5%
Human Albumin
5%
Immunology and Microbiology
Intravenous Immunoglobulin
66%
Low Drug Dose
38%
Chronic Inflammatory Demyelinating Polyneuropathy
38%
Drug Megadose
33%
Solution and Solubility
11%
Dose
11%
Skin Allergy
5%
Reduction (Chemistry)
5%
Voice
5%
Pharmacology, Toxicology and Pharmaceutical Science
Immunoglobulin
66%
Chronic Inflammatory Demyelinating Polyneuropathy
38%
Adverse Event
11%
Blindness
11%
Recurrence Risk
5%
Skin Allergy
5%
Human Albumin
5%
Polyneuropathy
5%
Relapse
5%